“CannPal is a pet pharmaceutical Company that has identified an opportunity to benefit from the rapidly growing medical cannabis sector, by developing standardised and dosage controlled, regulatory approved pharmaceuticals, derived from the cannabis plant”

Real Problems

We are committed to learning how cannabis can influence the therapeutic functions in cats and dogs, in the hopes that we can provide veterinarians with clinically validated and standardised therapeutic products to treat companion animals in a safe and ethical way.

ABOUT

Real Experts

The Company has engaged with strategic partners and research organizations for access to data and pre-clinical research into the safety and efficacy of cannabinoids in completed human trials and rodent studies, to pre-validate the Company’s therapeutic pipeline.

OUR RESEARCH

Real Solutions

Our research to date indicates it is possible to directly target receptors in the mammalian body using exogenous cannabinoids found in the cannabis plant to influence a number of physiological functions incompanions animals by balancing out cannabinoid deficiencies.

OUR INVESTORS

Innovators

The animal population is ageing and age related disease is growing at a quicker rate than new product innovation and development.

It’s estimated that over 60% of dogs between the ages of 7 and 11 years will experience arthritis, 1 in 2 will get some form of cancer and 1 in 4 dogs will die from the disease. 61% of felines over the age of 6 have Arthritis in at least 1 joint and 30% will be affected by a tumour at some point in their lives.

The medication available to pets for these indications can provide negative side effects including nausea, loss of appetite, depression and internal bleeding. Pets are also becoming increasingly resistant to non-steroidal anti-inflammatory drugs and other pharmaceutical therapies.

CannPal is working to further explore the natural healing abilities of cannabinoids, to develop novel and efficacious therapies for your companions, without the associated negative side effects, to enhance their quality of life.

Want more information ? Get in touch with us here.

Latest News

$25.955 0.005 / 0.02% Source: ASX Code: BHP
Delayed 20 minutes
25/09/2017
03:34:24PM